Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neurofibroma × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 123 Leukemia 61 Gastrointestinal Stromal Tumors 61 Leukemia, Myeloid, Chronic-Phase 45 Precursor Cell Lymphoblastic Leukemia-Lymphoma 37 Blast Crisis 19 Philadelphia Chromosome 14 Brain Neoplasms 14 Melanoma 12 Neoplasms 11 Neoplasm Metastasis 11 Lung Neoplasms 11 Glioblastoma 11 Leukemia, Myeloid, Acute 10 Leukemia, Myeloid, Accelerated Phase 10 Sarcoma 9 Gliosarcoma 9 Prostatic Neoplasms 8 Leukemia, Myeloid 8 Glioma 8 Central Nervous System Neoplasms 7 Primary Myelofibrosis 6 Oligodendroglioma 6 Dermatofibrosarcoma 6 Carcinoma, Non-Small-Cell Lung 6 Breast Neoplasms 6 Astrocytoma 6 Small Cell Lung Carcinoma 5 Recurrence 5 Ovarian Neoplasms 5

Interventions

mirdametinib 2 tipifarnib 1 talimogene laherparepvec 1 peginterferon alfa-2b 1 nilotinib 1 binimetinib 1 antineoplaston AS 2-1 1 antineoplaston A10 1 Vincristine 1 Temozolomide 1 Talaporfin 1 Sirolimus 1 Restraint, Physical 1 Ranibizumab 1 Radiosurgery 1 Photochemotherapy 1 Neurofibromin 1 1 Mn-PyC3A 1 Imatinib Mesylate 1 Everolimus 1 Elasticity Imaging Techniques 1 Deoxycholic Acid 1 Cryotherapy 1 Celecoxib 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01140360 2017-07-02

0908-09

Indiana University

Phase 1/2 Completed

21 enrolled 8 charts

Neurofibroma, Neurofibromatoses

Data powered by HemOnc (CC BY 4.0) Colophon ⚡